A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors (NCT06036836)
MK-4280A-010
This trial is No longer recruiting
Registration number NCT06036836
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 2
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Mark Voskoboynik
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR